What are the myalgia side effects associated with rosuvastatin, simvastatin, and atorvastatin?

Myalgia Risk Among Rosuvastatin, Simvastatin, and Atorvastatin

All three statins cause myalgia at similar rates overall, but when comparing equivalent doses, moderate-intensity atorvastatin appears to have the lowest risk of severe muscle complications (CK elevation >10×ULN) compared to simvastatin and pravastatin, while rosuvastatin 10 mg shows particularly low myalgia incidence (10.8%) in real-world data.

Comparative Myalgia Rates

Rosuvastatin

• Dose-dependent myalgia rates from FDA trials 1:
  • 5 mg: 3.1%
  • 10 mg: 2.1%
  • 20 mg: 6.3%
  • 40 mg: 1.9%
• In the JUPITER trial (20 mg): 7.6% vs 6.6% placebo 1
• Real-world data shows rosuvastatin 10 mg had only 10.8% myalgia incidence, among the lowest rates observed 2

Simvastatin

• Simvastatin 40 mg showed the highest myalgia rate at 50% in prospective cohort data 2
• Moderate-intensity simvastatin had 6.57 times higher risk of CK >10×ULN compared to moderate atorvastatin 3

Atorvastatin

• Atorvastatin 80 mg caused myalgia in 19 of 210 subjects (9%) vs 10 of 210 on placebo (4.8%) in the STOMP trial 4
• Moderate-intensity atorvastatin demonstrated superior muscle tolerability compared to equivalent doses of simvastatin and pravastatin 3
• No significant differences in adverse events when comparing rosuvastatin to atorvastatin at 1:1:2, or 1:4 dose ratios 5

Key Clinical Insights

Overall Risk Profile

The 2013 Canadian Working Group guidelines emphasize that no statistical difference in tolerability exists between atorvastatin, rosuvastatin, pravastatin, and fluvastatin after documented simvastatin-induced myopathy 6. However, this applies to statin rechallenge scenarios, not initial therapy selection.

Dose Considerations

• Moderate-intensity statins showed higher muscle symptoms than control (RR=1.13) in network meta-analysis 3
• Higher potency statins at lower doses may provide better tolerability than lower potency statins at higher doses
• Rosuvastatin 5 mg intermittently (2-3 times weekly) reduced myalgia while maintaining 32% LDL-C reduction 6

Practical Management Algorithm

When selecting initial statin therapy:

1. Start with rosuvastatin 10 mg or moderate-intensity atorvastatin - both show favorable myalgia profiles
2. Avoid simvastatin 40 mg - highest documented myalgia rate (50%) 2
3. Consider patient-specific risk factors that increase myopathy risk 1:
   • Age ≥65 years
   • Asian descent
   • Uncontrolled hypothyroidism
   • Renal impairment
   • Concomitant fibrates, cyclosporine, or certain antivirals

If myalgia develops:

1. 92% of patients successfully tolerate statin rechallenge - don't abandon statin therapy 6
2. Switch to a different statin (62-81% may develop cross-reactivity, but many succeed) 6
3. Try intermittent dosing (weekly rosuvastatin 5-10 mg achieved >10% LDL-C reduction) 6
4. Do not use supplements (CoQ10, vitamin D) to treat myalgia - no consistent evidence supports continuation of statins 6

Critical Pitfalls

• Atorvastatin 80 mg increased average CK by 20.8 U/L even in asymptomatic subjects 4 - mild muscle injury occurs even without symptoms
• Myalgia without CK elevation is common and often not dose-related 6
• Fluvastatin XL 80 mg showed only 8% myalgia incidence - consider for highly intolerant patients 2
• Lipophilic vs hydrophilic properties and CYP3A4 metabolism do not predict muscle adverse events 3

The evidence suggests that while all statins carry myalgia risk, starting with rosuvastatin 10 mg or moderate-intensity atorvastatin provides the best balance of efficacy and muscle tolerability, with simvastatin 40 mg being the least favorable option for muscle safety.